Rescuing the function of mutant p53 - PubMed

Review

Rescuing the function of mutant p53

A N Bullock et al. Nat Rev Cancer. 2001 Oct.

Abstract

One protein--p53--plays nemesis to most cancers by condemning damaged cells to death or quarantining them for repair. But the activity of p53 relies on its intact native conformation, which can be lost following mutation of a single nucleotide. With thousands of such mutations identified in patients, how can a future cancer drug buttress this fragile protein structure and restore the cell's natural defence?

Similar articles

• Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.

  Suad O, Rozenberg H, Brosh R, Diskin-Posner Y, Kessler N, Shimon LJ, Frolow F, Liran A, Rotter V, Shakked Z. Suad O, et al. J Mol Biol. 2009 Jan 9;385(1):249-65. doi: 10.1016/j.jmb.2008.10.063. Epub 2008 Oct 30. J Mol Biol. 2009. PMID: 18996393

• Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.

  Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C. Kato S, et al. Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8424-9. doi: 10.1073/pnas.1431692100. Epub 2003 Jun 25. Proc Natl Acad Sci U S A. 2003. PMID: 12826609 Free PMC article.

• Characterization of the p53-rescue drug CP-31398 in vitro and in living cells.

  Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG, Fersht AR. Rippin TM, et al. Oncogene. 2002 Mar 28;21(14):2119-29. doi: 10.1038/sj.onc.1205362. Oncogene. 2002. PMID: 11948395

• p53--a natural cancer killer: structural insights and therapeutic concepts.

  Römer L, Klein C, Dehner A, Kessler H, Buchner J. Römer L, et al. Angew Chem Int Ed Engl. 2006 Oct 6;45(39):6440-60. doi: 10.1002/anie.200600611. Angew Chem Int Ed Engl. 2006. PMID: 16983711 Review.

• Reactivation of mutant p53: molecular mechanisms and therapeutic potential.

  Selivanova G, Wiman KG. Selivanova G, et al. Oncogene. 2007 Apr 2;26(15):2243-54. doi: 10.1038/sj.onc.1210295. Oncogene. 2007. PMID: 17401433 Review.

Cited by

• The regulatory role and clinical application prospects of circRNA in the occurrence and development of CNS tumors.

  Zhang B, Zhang H, Wang Z, Cao H, Zhang N, Dai Z, Liang X, Peng Y, Wen J, Zhang X, Zhang L, Luo P, Zhang J, Liu Z, Cheng Q, Peng R. Zhang B, et al. CNS Neurosci Ther. 2024 Apr;30(4):e14500. doi: 10.1111/cns.14500. Epub 2023 Nov 12. CNS Neurosci Ther. 2024. PMID: 37953502 Free PMC article. Review.

• DISPLAR: an accurate method for predicting DNA-binding sites on protein surfaces.

  Tjong H, Zhou HX. Tjong H, et al. Nucleic Acids Res. 2007;35(5):1465-77. doi: 10.1093/nar/gkm008. Epub 2007 Feb 6. Nucleic Acids Res. 2007. PMID: 17284455 Free PMC article.

• Reversible aggregation plays a crucial role on the folding landscape of p53 core domain.

  Ishimaru D, Lima LM, Maia LF, Lopez PM, Ano Bom AP, Valente AP, Silva JL. Ishimaru D, et al. Biophys J. 2004 Oct;87(4):2691-700. doi: 10.1529/biophysj.104.044685. Epub 2004 Aug 6. Biophys J. 2004. PMID: 15298872 Free PMC article.

• Revisiting the myths of protein interior: studying proteins with mass-fractal hydrophobicity-fractal and polarizability-fractal dimensions.

  Banerji A, Ghosh I. Banerji A, et al. PLoS One. 2009 Oct 16;4(10):e7361. doi: 10.1371/journal.pone.0007361. PLoS One. 2009. PMID: 19834622 Free PMC article.

• Genetic alterations in anaplastic thyroid carcinoma and targeted therapies.

  Li Z, Zhang Y, Wang R, Zou K, Zou L. Li Z, et al. Exp Ther Med. 2019 Oct;18(4):2369-2377. doi: 10.3892/etm.2019.7869. Epub 2019 Aug 8. Exp Ther Med. 2019. PMID: 31555347 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal